Artemisinin, an anti-malarial agent, inhibits rat cardiac hypertrophy via inhibition of NF-κB signaling

European Journal of Pharmacology

Volumn 649, Issue 1-3, 2010, Pages 277-284

  Xiong, Zhaojun ^a   Sun, Gang ^a   Zhu, Cansheng ^a   Cheng, Baolin ^a   Zhang, Chengxi ^a   Ma, Yuedong ^a   Dong, Yugang ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Artemisinin; Cardiac hypertrophy; I B ; NF B

Indexed keywords

ANGIOTENSIN II; ARTEMISININ; HETERODIMER; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN P50; SMALL INTERFERING RNA; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA SURGERY; ARTICLE; BINDING AFFINITY; BODY WEIGHT; CELL GROWTH; CELL TRANSFORMATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE MARKER; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ECHOCARDIOGRAPHY; EXPERIMENTAL MODEL; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC TRANSFECTION; HEART MUSCLE CELL; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; IN VITRO STUDY; IN VIVO STUDY; LUNG WEIGHT; MALE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RAT; SIGNAL TRANSDUCTION; TREATMENT DURATION;

ANIMALS; ANIMALS, NEWBORN; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIMALARIALS; ARTEMISININS; CARDIOMEGALY; CARDIOTONIC AGENTS; CELLS, CULTURED; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; HEART; I-KAPPA B PROTEINS; MALE; MYOCARDIUM; MYOCYTES, CARDIAC; NF-KAPPA B; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 78049283326     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.09.018     Document Type: Article

References (23)

1. Aldieri E., Atragene D., Bergandi L., Riganti C., Costamagna C., Bosia A., Ghigo D. Artemisinin inhibits inducible nitric oxide synthase and nuclear factor NF-κB activation. FEBS Lett. 2003, 552:141-144.
2. Baldwin A.S. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu. Rev. Immunol. 1996, 14:649-683.
3. Chien K.R. Stress pathways and heart failure. Cell 1999, 98:555-558.
4. Dignam D.J., Lebovitz R.M., Roeder R.G. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res. 1983, 11:1475-1489.
5. Dorn G.W., Robbins J., Sugden P.H. Phenotyping hypertrophy: eschew obfuscation. Circ. Res. 2003, 92:1171-1175.
6. Efferth T. Molecular pharmacology and pharmacogenomics of artemisinin and its derivatives in cancer cells. Curr. Drug Targets 2006, 7:407-421.
7. Frey N., Olson E.N. Cardiac hypertrophy: the good, the bad, and the ugly. Annu. Rev. Physiol. 2003, 65:45-79.
8. Gupta S., Purcell N.H., Lin A., Sen S. Activation of nuclear factor-kappaB is necessary for myotrophin-induced cardiac hypertrophy. J. Cell Biol. 2002, 159:1019-1028.
9. Haynes R.K. Artemisinin and derivatives: the future for malaria treatment?. Curr. Opin. Infect. Dis. 2001, 14:719-726.
10. Higuchi Y., Otsu K., Nishida K., Hirotani S., Nakayama H., Yamaguchi O., Matsumura Y., Ueno H., Tada M., Hori M. Involvement of reactive oxygen speciesmediated NF-kappa B activation in TNF-alpha-induced cardiomyocyte hypertrophy. J. Mol. Cell. Cardiol. 2002, 34:233-240.
11. Karin M., Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu. Rev. Immunol. 2000, 18:621-633.
12. Kawano S., Kubota T., Monden Y., Kawamura N., Tsutsui H., Takeshita A., Sunagawa K. Blockade of NF-kappaB ameliorates myocardial hypertrophy in response to chronic. infusion of angiotensin II. Cardiovasc. Res. 2005, 69:689-698.
13. Li H.L., Yin R., Chen D., Liu D., Wang D., Yang Q., Dong Y.G. Long-term activation of adenosine monophosphate-activated protein kinase attenuates pressure-overload-induced cardiac hypertrophy. J. Cell. Biochem. 2007, 100:1086-1099.
14. Nontprasert A., Pukrittayakamee S., Dondorp A.M., Clemens R., Looareesuwan S., White N.J. Neuropathologic toxicity of artemisinin derivatives in a mouse model. Am. J. Trop. Med. Hyg. 2002, 67:423-429.
15. Purcell N.H., Tang G.L., Yu C.F., Mercurio F., DiDonato J.A., Lin A.N. Activation of NF-kappa B is required for hypertrophic growth of primary rat neonatal ventricular cardiomyocytes. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:6668-6673.
16. Ritchie M.E. Nuclear factor-kappaB is selectively and markedly activated in humans with unstable angina pectoris. Circulation 1998, 98:1707-1713.
17. Seshiah P.N., Weber D.S., Rocic P., Valppu L., Taniyama Y., Griendling K.K. Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators. Circ. Res. 2002, 91:406-413.
18. Simpson P. Norepinephrine-stimulated hypertrophy of cultured rat myocardial cells is an alpha 1 adrenergic response. J. Clin. Invest. 1983, 72:732-738.
19. Wang Z., Qiu J., Guo T.B., Liu A., Wang Y., Li Y., Zhang J.Z. Anti-inflammatory properties and regulatory mechanism of a novel derivative of artemisinin in experimental autoimmune encephalomyelitis. J. Immunol. 2007, 179:5958-5965.
20. Wartenberg M., Wolf S., Budde P., Grünheck F., Acker H., Hescheler J., Wartenberg G., Sauer H. The antimalaria agent artemisinin exerts antiangiogenic effects in mouse embryonic stem cell-derived embryoid bodies. Lab. Invest. 2003, 83:1647-1655.
21. White N.J. Antimalarial drug resistance. J. Clin. Invest. 2004, 113:1084-1092.
22. Wong S.C., Fukuchi M., Melnyk P., Rodger I., Giaid A. Induction of cyclooxygenase-2 and activation of nuclear factor-kappaB in myocardium of patients with congestive heart failure. Circulation 1998, 98:100-103.
23. Xu H., He Y., Yang X., Liang L., Zhan Z., Ye Y., Yang X., Lian F., Sun L. Anti-malarial agent artesunate inhibits TNF-alpha-induced production of proinflammatory cytokines via inhibition of NF-kappaB and PI3 kinase/Akt signal pathway in human rheumatoid arthritis fibroblast-like synoviocytes. Rheumatology (Oxford) 2007, 46:920-926.